<DOC>
	<DOCNO>NCT01387815</DOCNO>
	<brief_summary>The current study compare real - life effectiveness adalimumab topical traditional systemic agent management psoriasis impact patient 's quality life societal burden illness .</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Effectiveness Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Active moderate severe Plaque PS accord judgment treat physician . The treat physician decide change current treatment add additional treatment reason include limited inadequate response , intolerance , suboptimal compliance patient preference . Currently participate another prospective study similar objective . Patient sign inform consent . Presence condition , opinion treat physician , prohibits patient participate study obscures assessment treatment Plaque PS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Topical Agents</keyword>
	<keyword>Observational</keyword>
	<keyword>Traditional Systemic Agents</keyword>
	<keyword>Prospective</keyword>
	<keyword>Comparative</keyword>
	<keyword>Effectiveness</keyword>
</DOC>